Veru Inc. (VERU)
| Market Cap | 44.76M -11.9% |
| Revenue (ttm) | n/a |
| Net Income | -13.61M |
| EPS | -0.67 |
| Shares Out | 17.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,787 |
| Open | 2.710 |
| Previous Close | 2.740 |
| Day's Range | 2.610 - 2.730 |
| 52-Week Range | 2.050 - 7.330 |
| Beta | -1.20 |
| Analysts | Strong Buy |
| Price Target | 24.50 (+833.33%) |
| Earnings Date | Aug 10, 2026 |
About VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $24.5, which is an increase of 833.33% from the latest price.
News
Veru Inc. Earnings Call Transcript: Q3 2026
Enrollment completed for the phase IIb PLATEAU trial of enobosarm with interim results expected Q1 2027. Net loss narrowed year-over-year, cash position improved, and a key patent was secured, extending protection to at least 2044.
Veru Inc. Earnings release: Q3 2026
Veru Inc. released its Q3 2026 earnings on August 10, 2026, summarizing the period's financial results.
Veru Inc. Quarterly report: Q3 2026
Veru Inc. has published its Q3 2026 quarterly earnings report on August 10, 2026.
Veru reports Q3 EPS (30c) vs. (50c) last year
“We are extremely pleased with the continued enobosarm progress during this past quarter,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru (VERU) Inc. “We reached...
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of ...
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru completes enrollment in PLATEAU clinical study
Veru (VERU) announced the completion of enrollment in the Phase 2b PLATEAU clinical study to evaluate the effect of oral enobosarm 3 mg versus placebo on total body weight, fat…
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. ...
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru pact with Novo ‘significant event,’ says Canaccord
Canaccord keeps a Buy rating on Veru (VERU) with a $25 price target after the company disclosed a supply agreement with Novo Nordisk (NVO) for Wegovy. The news is a…
Veru announces clinical supply agreement with Novo Nordisk
In a regulatory filing, Veru (VERU) announced that on June 2, the company entered into a clinical supply agreement with Novo Nordisk A/S (NVO) in conjunction with the company’s Phase…
Veru price target lowered to $24 from $25 at Oppenheimer
Oppenheimer lowered the firm’s price target on Veru (VERU) to $24 from $25 to reflect the company’s Q2 results. The firm keeps an Outperform rating on the shares. Published first…
Veru Inc. Earnings Call Transcript: Q2 2026
Enobosarm showed strong phase II-B results in preserving lean mass and function in older obese patients on GLP-1 therapy, with a large market opportunity and ongoing phase II-B plateau study. Net loss narrowed and cash position improved, supporting continued R&D.
Veru Inc. Earnings release: Q2 2026
Veru Inc. released its Q2 2026 earnings on May 13, 2026, summarizing the period's financial results.
Veru Inc. Quarterly report: Q2 2026
Veru Inc. has published its Q2 2026 quarterly earnings report on May 13, 2026.
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic an...
Veru files $200M mixed securities shelf
16:22 EDT Veru (VERU) files $200M mixed securities shelf
Veru files to sell 23.8M shares of common stock
16:16 EDT Veru (VERU) files to sell 23.8M shares of common stock
Veru Inc. Registration statement: Registration filing
Veru Inc. filed a registration statement on April 7, 2026, providing details about a securities offering with the SEC.
Veru Inc. Registration statement: Registration filing
Veru Inc. filed a registration statement on April 7, 2026, providing details about a securities offering with the SEC.
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm
Veru (VERU) announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator, SARM, to preserve muscle and…
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients...